The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study

Blood

Volumn 101, Issue 8, 2003, Pages 2955-2959

  Girolami, Bruno ^b   Prandoni, Paolo ^a   Stefani, Piero M ^b   Tanduo, Cinzia ^b   Sabbion, Paola ^b   Eichler, Petra ^b   Ramon, Roberto ^b   Baggio, Giovannella ^b   Fabris, Fabrizio ^b   Girolami, Antonio ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WARD; ADOLESCENT; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; HOSPITAL DEPARTMENT; HOSPITAL PATIENT; IMMUNOLOGY; INCIDENCE; INTERNAL MEDICINE; ITALY; METABOLISM; MIDDLE AGED; PREVALENCE; STATISTICS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AUTOIMMUNE DISEASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HOSPITAL DEPARTMENTS; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; INPATIENTS; INTERNAL MEDICINE; ITALY; MALE; MIDDLE AGED; PLATELET FACTOR 4; PREVALENCE; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0038243178     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2201     Document Type: Article

References (20)

1. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136:409-416.
2. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med. 1976;295:237-241.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engi J Med. 1995;332:1330-1335.
4. Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore PJ, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
5. Warkentin T, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
6. Amiral J, Bridey F, Dreyfus M, et al. Platelet Factor 4 complexed to heparin is the target for antibodies in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
7. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
8. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
9. Kelton JC, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood F. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
10. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
11. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(suppl 5):9-16.
12. Chong BH. Heparin induced thrombocytopenia. Aust N Z J Med. 1992;22:145-152.
13. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305:208-215.
14. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2001;10:35-45.
15. Eichler P, Budde U, Haas S, et al. First workshop for the detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with PF4/heparin ELISA. Thromb Haemost. 1999;81:625-629.
16. Geerts WH, Heit JH, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(suppl):132-175.
17. Caprini JA, Arcelus J, Sehgal LR, Cohen EB, Reyna JJ. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Int Angiol. 2002;21:78-85.
18. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(suppl):64-94.
19. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210-215.
20. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502-506.